Dr. Hayati Yaakup, Palliative Care Unit, Department of Internal Medicine, Faculty of Medicine, Universiti Kebangsaan Malaysia, Jalan Yaacob Latiff, Bandar Tun Razak, 56000 Cheras, Kuala Lumpur, Malaysia, Tel: +60391456074, Fax: +60391456692, Email:
J Nutr Health Aging. 2020;24(10):1066-1072. doi: 10.1007/s12603-020-1494-1.
To evaluate the impact of a microbial cell preparation (MCP®) (Hexbio®; comprising MCP® BCMC® strains) on stool frequency, consistency, and constipation-related symptoms in elderly patients with multiple chronic medical conditions.
Randomised control trial.
Medical outpatient and medical/surgical in-patient unit in single tertiary center.
Patients aged ≥ 60 years who experience constipation and have multiple chronic medical conditions.
Participants with constipation were blindly randomized into either a treatment (MCP® BCMC® strains) or a placebo group. The treatment was administered twice daily.
Gastrointestinal symptoms and stool habits were assessed over a week during the intervention via the use of a questionnaire and stool diary.
Stool frequency was seen to be higher and the improvement in stool consistency was more significant in the treatment group than in the placebo group (p =<0.001). A significant improvement in symptoms was demonstrated in patients who received MCP® BCMC® strains,specifically with respect to straining (p = < 0.001) and a sensation of incomplete evacuation (p = < 0.001). reduction in anorectal blockage symptoms and the need for manual stool evacuation was also demonstrated, but this finding was not statistically significant. Significant adverse events were not observed.
An improvement in stool frequency and consistency was reported in elderly patients with chronic medical conditions following the administration of MCP® BCMC® strains.
评估微生物细胞制剂(MCP®)(Hexbio®;包括 MCP® BCMC® 菌株)对患有多种慢性疾病的老年患者的粪便频率、稠度和与便秘相关症状的影响。
随机对照试验。
单一三级中心的医疗门诊和医疗/外科住院病房。
患有便秘且患有多种慢性疾病的年龄≥60 岁的患者。
患有便秘的参与者被盲法随机分为治疗(MCP®BCMC®菌株)或安慰剂组。治疗每天两次给药。
通过使用问卷和粪便日记在干预期间的一周内评估胃肠道症状和粪便习惯。
与安慰剂组相比,治疗组的粪便频率更高,粪便稠度的改善更明显(p<0.001)。接受 MCP®BCMC®菌株治疗的患者的症状明显改善,特别是在用力排便(p<0.001)和感觉不完全排空(p<0.001)方面。还显示出减少肛门直肠阻塞症状和需要手动排便的情况,但这一发现没有统计学意义。未观察到显著的不良反应事件。
在患有慢性疾病的老年患者中,给予 MCP®BCMC®菌株后,粪便频率和稠度均有所改善。